Influvac

Influenza virus vaccine, the active ingredient in Influvac, is a vaccine presented as a vaccine formulation for intramuscular and subcutaneous use. It stimulates the immune system to produce antibodies against the included influenza A (Victoria) and influenza B (Austria) strains, providing protection against seasonal flu in children and adults.

GNH USA supplies Influvac as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides cold‑chain logistics to ensure product integrity.

Influvac is indicated for immunization against influenza viruses, targeting the seasonal flu pathway. - Seasonal influenza: reduces the risk of laboratory‑confirmed influenza infection in the general population. - High‑risk groups (elderly, chronic disease patients): provides enhanced protection to lower rates of severe illness and hospitalization. - Travelers to regions with active flu activity: helps prevent infection during travel and reduces transmission risk. - Outbreak control in community settings: contributes to herd immunity and limits spread of influenza A and B strains.

Common and serious adverse reactions may occur following administration of Influvac. Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection site. - Redness or swelling: localized erythema or edema lasting a few days. - Low‑grade fever: transient temperature rise within 24 hours. Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Guillain‑Barré syndrome: rare neurological disorder potentially triggered post‑vaccination. - Seizures: infrequent convulsive episodes, especially in children with fever.

Before administering Influvac, consider the following precautions to ensure safety and efficacy. - Allergy assessment: verify no known hypersensitivity to egg proteins or any vaccine component. - Acute illness: postpone vaccination if the recipient has a moderate or severe febrile illness. - Immunocompromised status: consult a healthcare professional for individuals with weakened immune systems. - Age restrictions: follow local guidelines for minimum and maximum age limits for vaccination. - Concomitant vaccines: separate administration from live vaccines by at least four weeks when possible. - Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake the vial.

Vaccines may interact with certain medical conditions or therapies; the following interactions are recognized for Influvac. Major Interactions (Avoid): - Severe egg allergy: contraindicates use due to vaccine residual egg proteins. - Recent receipt of blood products: may diminish immune response if given within three months. - Immunosuppressive therapy: inactivated influenza vaccine may have reduced efficacy; consult physician. Moderate Interactions (Monitor Closely): - Antiviral medications (e.g., oseltamivir): may interfere with immune response if taken concurrently. - Chronic corticosteroid use: may lower antibody production, monitor serologic response. - Pregnancy: vaccine is generally considered safe, but discuss timing with obstetrician.